Alumis Inc. (ALMS)

Alumis, Inc.'s stock has experienced significant events, including a substantial increase of 370.38% over the last 12 months, with a year-to-date return of 142.42% as of May 9, 2026. In January 2026, Alumis completed an upsized underwritten public offering, generating approximately $345.1 million in gross proceeds. Positive Phase 3 data for envudeucitinib in moderate-to-severe plaque psoriasis were announced in January 2026, with full data presented in March 2026. Following these positive results, several analysts reiterated or initiated positive ratings and adjusted price targets upwards. Insider buying activity also sparked positive sentiment. However, the company's latest quarterly earnings in March 2026 reported an EPS of ($0.95) and revenue of $1.93 million, missing consensus estimates.

As a clinical-stage biopharmaceutical company, the demand for Alumis, Inc.'s products and services is not typically subject to seasonal fluctuations. Demand is primarily driven by the prevalence of the diseases it aims to treat and the efficacy and regulatory approval of its therapeutic candidates, rather than seasonal patterns.

Alumis, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines for autoimmune disorders, addressing unmet medical needs in conditions like plaque psoriasis and systemic lupus erythematosus. Its major product candidates include envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus, and A-005, a central nervous system (CNS)-penetrant allosteric TYK2 inhibitor in Phase 1 development for neuroinflammatory and neurodegenerative diseases. The company also develops lonigutamab, a monoclonal antibody targeting IGF-1R for thyroid eye diseases, and interferon regulatory factor 5 (IRF5) to address immune dysfunction. Alumis was incorporated in 2021 and was formerly known as Esker Therapeutics, Inc., changing its name in January 2022.

Alumis, Inc. is headquartered in South San Francisco, California, United States.

Alumis, Inc. generally holds a positive brand reputation, particularly among analysts, with a consensus rating of "Strong Buy" or "Moderate Buy" as of May 9, 2026. This positive sentiment is largely driven by strong Phase 3 clinical trial data for its lead drug candidate, envudeucitinib. The anticipation of upcoming clinical data releases for treatments in psoriasis and lupus in 2026 also contributes to cautious optimism. Insider buying has also been interpreted as a strong vote of confidence in the company's future.

Alumis Inc. is primarily owned by institutional shareholders (62.16%), followed by Alumis insiders (23.09%), and retail investors (14.74%). The company has 146 institutional owners and shareholders holding a total of 73,730,057 shares. Major institutional owners include AyurMaya Capital Management Company, LP, Foresite Capital Management V, LLC, Samsara BioCapital, LLC, venBio Partners LLC, BlackRock, Inc., Foresite Capital Management VI LLC, Vanguard Group Inc, Saturn V Capital Management LLC, Octagon Capital Advisors LP, and MPM Oncology Impact Management LP. Ayurmaya Capital Management Company LP is also the largest individual shareholder, owning 15.14 million shares, representing 11.90% of the company.